D&D sees fibrosis improvements, MASH resolution after rolling dice on GLP-1 drug
D&D Pharmatech has linked its GLP-1/glucagon receptor agonist to improvements in liver health, keeping the Korean biotech in the hunt for a market already serve...
D&D Pharmatech has linked its GLP-1/glucagon receptor agonist to improvements in liver health, keeping the Korean biotech in the hunt for a market already served by Novo Nordisk’s Wegovy.